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ABSTRACT
Inhaled fixed-dose combinations (FDCs) of a
long-acting b-agonist (LABA) and a long-acting
muscarinic antagonist (LAMA) have become the
cornerstone for the maintenance treatment of
symptomatic COPD patients. In this regard,
global COPD treatment guidelines have recog-
nized the importance of inhaler devices as inte-
gral contributors to the effectiveness of LABA/
LAMA FDCs and recommend regular assessment
of inhaler device use by the patients in order to
improve long-term clinical outcomes. Optimal
disease control is also highly dependent upon
patient preferences and adherence to inhaler
devices. This review objectively examines and
compares the major inhaler devices used to
deliver different LABA/LAMA FDCs, discusses the
inhaler device characteristics that determine
drug deposition in the airways, real-life prefer-
ence for inhaler devices, and handling of inhaler
devices that impact the results of the long-term
management of COPD. The introduction of new
LABA/LAMA FDCs, new inhaler devices, and
more clinical studies have created confusion
among physicians in choosing the optimal
inhaled therapy for COPD patients; in this con-
text, this review attempts to provide an evidence-
based framework for informed decision-making
with a particular focus on the inhaler devices.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is an increasingly common respiratory disease
caused by substantial long-term exposure to
noxious particles or gases and marked by per-
sistent respiratory symptoms and airflow limi-
tation [1]. COPD affects an estimated
210 million people worldwide [2]. By 2030,
COPD is projected to be the third leading cause
of mortality globally [3]. The significant eco-
nomic burden imposed by COPD continues to
increase both in terms of direct and indirect
healthcare costs [4, 5].
The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) report provides a
strategy for the assessment and management of
COPD and suggests categorizing these patients
into four groups, A–D, based on symptoms and
exacerbation history [6]. Inhaled therapy is
fundamental in all classes of COPD patients.
GOLD recommends the combination of a long-
acting b-agonist (LABA) and a long-acting
muscarinic antagonist (LAMA) as the first-line
treatment for patients in GOLD groups B and
D, i.e., patients with high symptom burden
and those who are at a greater risk of exacer-
bations, respectively. Starting with LABA/LAMA
combination therapy is recommended on the
basis of the greater efficacy of this therapy in
improving lung function, symptoms, quality of
life, and in reducing exacerbations when com-
pared to monotherapy or to LABA/inhaled
corticosteroid (ICS) combinations in these
patients [6–15].
The current GOLD strategy has explicitly
recognized the importance of inhaler choice
and instructions in the context of COPD man-
agement. Moreover, for the first time, GOLD
2019 has recommended to consider switching
molecules and/or inhaler devices within classes
to improve response/outcomes [6]. Following
careful device selection tailored to individual
patient needs and abilities, the importance of
initial education and training in inhaler device
technique is emphasized. Regular reassessment
of inhaler technique has been recommended to
improve long-term therapeutic outcomes.
Finally, before concluding that the current
treatment is insufficient, inhaler technique (and
adherence to therapy) should be reviewed [6].
The GOLD strategy has also recognized the
importance of delivering more than one drug
via a single inhaler device, especially in light of
the evidence that use of multiple devices
requiring different inhalation techniques
diminishes the effectiveness of therapy [16].
Long known to being a critical issue in asthma
management, ensuring adequate inhalation
technique may be of even greater importance in
older COPD patients who are more likely to
have debilitating comorbidities such as arthritis
of the hands and typically have far less venti-
lator reserve [17, 18].
Fixed-dose combinations (FDCs) of LABA/
LAMA have become the foundation of COPD
treatment and this article provides an overview
of the key aspects of inhaler devices that are
used to deliver this therapy in FDCs to patients
with COPD. More importantly, this review is
aimed to provide guidance to physicians on
evaluating device characteristics and ensuring
correct inhaler use by patients, in light of the
renewed focus on patients’ ability to use these
devices correctly for optimal treatment out-
comes. We describe key inhaler device-related
factors that influence the patients’ and physi-
cians’ perception of devices, ultimately
impacting the effectiveness of LABA/LAMA
combination therapy in COPD.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
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DELIVERY OF LABA/LAMA
COMBINATION THERAPY TO COPD
PATIENTS
Several devices are available to deliver LABA/
LAMA in a FDC to COPD patients and each
device has its own features that should be con-
sidered when tailoring treatment to specific
patient needs. These devices include pressurized
metered-dose inhalers (pMDIs), dry powder
inhalers (DPIs), and soft-mist inhaler (SMI) [19]
and are listed in Table 1.
The pMDIs are widely used because of their
small size and unobtrusive nature. Their use con-
tinues despite evidence of frequent coordination
errors and mishandling of these devices by
patients [20–23]. However, the CRITIKAL study
showed that poor coordination between the start
of an inhalation and actuation of the dose (i.e.,
actuation coming before inhalation) was a critical
error with MDIs that was associated with poor
disease outcomes [24]. The CRITIKAL study results
also indicated that exhaling into the mouthpiece
or not holding the inhaler upright was a critical
pMDI error; moreover, inspiratory effort was not
slow and deep enough in the majority of asthma
patients using a pMDI [24]. Lack of device
knowledge, incorrect second dose preparation,
timing, or inhalation, exhaling into the mouth-
piece, and not holding the inhaler upright have
also been identified as critical errors associated
with pMDIs [24–26]. A notable development has
been breath-activated pMDIs, which incorporate a
triggering mechanism that releases the dose when
a patient’s inspiratory effort is detected [21, 22].
The use of a valved holding chamber (a reservoir
with a one-way valve permitting airflow into the
patient’s mouth) to activate the pMDI before
inhalation has been propagated to eliminate
potentially critical inhaler handling errors and to
increase lung deposition of drug particles [27, 28].
The DPIs are devices containing drugs in
powdered formulation consisting of micronized
particles in a respirable range [29]. Most DPIs
allow the particles to be deagglomerated using
energy created by the patient’s own inspiratory
flow. These devices are available as single- and
multiple-dose configurations [29, 30]. DPIs are
breath-actuated and thus they do not have the
issue of coordinating actuation and inhalation
[31]. DPIs offer increased stability of drug for-
mulation, flexibility in inhaler design options,
and ability to achieve a high fine particle fraction
[32]. However, DPIs do have some inherent lim-
itations, e.g., variable airflow resistance, and
often the inability of patients to achieve ade-
quate inspiratory flow in order to mobilize the
dry powder medication. However, some patients
fail to generate sufficient inspiratory effort even if
they are capable of achieving it [33]. The CRITI-
KAL study showed that insufficient inspiratory
effort was a critical error associated with the use
of DPIs [24]. Although DPIs obviate the issue of
coordinating inhalation to an actuation, other
errors are seen such as incorrect loading and
preparation of the dose, blowing into the device,
and exposing multi-dose reservoir devices to
environmental moisture [24, 29, 33].
The SMI is a multiple-dose, propellant-free,
hand-held, liquid inhaler device that generates
an inhalable aerosol from a drug solution using
a patient-independent and reproducible energy
supply [34]. The aerosol plume generated by
this device is slower and lasts longer than
aerosol clouds from pMDIs [35]. Limitations of
the SMI include potential issues in dose prepa-
ration, the device being non-breath-actuated,
unavailability in many countries, and relatively
higher costs compared with other devices [36].
In the context of the limitations and advan-
tages of different classes of devices (Table 1), the
shift from pMDIs to DPIs and SMI signifies a
development in inhaled therapy. The newer
inhaler devices exclude propellants, minimize
patient limitations (including cognitive and psy-
chomotor impairment that may limit inhaler use)
and errors in handling the device, and improve
the consistency of drug delivery to the lungs. In
the subsequent sections, we describe representa-
tive devices from these classes of inhalers.
INHALER DEVICES AVAILABLE
FOR LABA/LAMA DELIVERY
Aerosphere
The Aerosphere (AstraZeneca Pharmaceuticals,
Wilmington, DE, USA) is a hydrofluoroalkane-
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propelled pMDI containing 20–180 inhalations
[37]. The canister has an attached dose indicator
and is supplied with an actuator body and
mouthpiece with a cap. Aerosphere contains
porous particles that form a co-suspension with
drug crystals; the porous particles are comprised
of the phospholipid 1,2-distearoyl-sn-glycero-3-
phosphocholine and calcium chloride. After
each actuation, the device delivers glycopyrro-
nium 7.2 lg and formoterol furoate 4.8 lg from
the actuator. Priming the Aerosphere before
the first dose is essential to ensure appropriate
drug content in each actuation; priming before
first use requires four sprays (actuations) into
the air away from the face, shaking well prior to
each spray [37].
Breezhaler
The Breezhaler (Novartis Pharma AG, Basel,
Switzerland) is a breath-actuated, single-dose,
capsule-based DPI used to deliver a variety of
medications, including indacaterol (a LABA),
glycopyrronium (a LAMA), indacaterol/gly-
copyrronium FDC and budesonide (an ICS)
[38]. In case of Ultibro Breezhaler, each
delivered dose contains 110 lg of indacaterol
maleate equivalent to 85 lg of indacaterol and
54 lg of glycopyrronium bromide equivalent to
43 lg of glycopyrronium [38]. The Breezhaler
requires the loading of a drug-containing cap-
sule prior to each inhalation. Generally, one
inhalation is enough to empty the capsule for
most patients. Should the capsule not com-
pletely empty upon a shallow and short inspi-
ration, e.g., low inhaled volume, patients will
see powder remaining in the capsule and can
therefore repeat the inhalation manoeuver. The
Breezhaler was designed to provide immediate
sensory feedback to the patient that the dose
has been administered correctly: by hearing a
distinctive ‘‘whirring’’ noise on correct inhala-
tion, by visually checking that the transparent
drug capsule is empty, and by tasting the lactose
excipient [38]. The Breezhaler has a low
intrinsic resistance; most patients are able to
generate the minimum inspiratory flow rate of
30 L/min with Breezhaler and the device pro-
vides consistent dose delivery using inspiratory
flow rates between 30 and 100 L/min [39–41].
Low-resistance devices such as Breezhaler
allow air to flow through them easily [41].
Owing to its low resistance, Breezhaler pro-
vided consistent dose delivery with regards to
both the delivered dose and fine particle mass
across the range of inhalation flow rates
achievable by COPD patients [42, 43]. Patients
with mild to very severe COPD have been
shown to use the Breezhaler device success-
fully, with a low device complaint rate
(\0.03%) and no device failures from approxi-
mately 90,000 recorded uses [38]. The Breezha-
ler was shown to deliver a higher fine particle
fraction and greater drug deposition in the
lungs (lower oropharyngeal drug deposition)
compared with the high-resistance HandiHaler
DPI [44]. Multiple steps are required for drug
administration with Breezhaler, which may
induce errors; regardless of this, the recent
large-scale real-world INHALER study showed
that patients committed fewest errors with
Breezhaler versus any other studied inhaler,
including pMDIs and SMIs [45].
Ellipta
The Ellipta DPI (GSK, Research Triangle Park,
NC, USA) is single-step activation, multiple-
dose inhaler that comes in a two-strip configu-
ration for delivery of LABA/LAMA combination
[46]. It was designed to deliver LABA/LAMA
dual bronchodilator FDC such as vilanterol and
umeclidinium [47]. Anoro Ellipta delivers
55 lg of umeclidinium and 22 lg of vilanterol
per dose. Compared with other DPIs, the
Ellipta device requires fewer steps for actuation
and use requiring only that the patient open the
mouthpiece cover fully, inhale the powder, and
close the mouthpiece [46, 47]. Ellipta has a
medium airflow resistance; in vitro data showed
that doses of drugs delivered via the Ellipta
device were consistent at inspiratory flow rates
of at least 30 L/min [31, 48]. This suggests that
Ellipta can be used even by patients with sev-
ere COPD notwithstanding that real-life use
may differ from that observed in randomized
controlled trials. A frequent error of insufficient
inhalation effort observed with Diskus in the
Pulm Ther (2019) 5:23–41 27
CRITIKAL study has also been observed with
Ellipta. In an in vitro study that replicated
inhaler-specific patient inhalation profiles that
were previously recorded in vivo using the
Electronic Lung (eLungTM), drug dose delivery
via the Ellipta DPI was consistent across the
range of patient representative inhalation
parameters for all therapies such as formoterol/
vilanterol, umeclidinium/vilanterol, and for-
moterol [49]. A recent study showed that
patients with mild to very severe COPD could
also generate sufficient inspiratory flows for
optimum drug delivery via Ellipta [50]; it
should be noted that this may not always be
true in real life.
Genuair
Genuair (AstraZeneca, Cambridge, UK) is a
multi-dose DPI designed to deliver inhaled
medications such as FDC of formoterol and
aclidinium to patients with COPD [51, 52]. Each
delivered dose contains 396 lg of aclidinium
bromide (equivalent to 340 lg of aclidinium)
and 11.8 lg of formoterol fumarate dihydrate.
The device is relatively easy to use: the patient
need only remove the cap on the mouthpiece,
press and release the green button at the back;
with successful inhalation the color of the
control window turns from green to red with an
audible click [52]. Genuair has a medium
resistance to inspiratory airflow and uses an
optimized dispersion system to ensure effective
deagglomeration of the inhalation powder
[52, 53]. Genuair has been shown to deliver a
consistent fine particle dose at inspiratory flow
rates of greater than 35 L/min [53, 54]. The
device provides a fine particle fraction averaging
40% [55]. A limitation for Genuair is the initial
flow acceleration which needs high effort.
Respimat
Respimat (Boehringer Ingelheim, Ingelheim,
Germany) is a multi-dose, propellant-free,
hand-held SMI that delivers FDC of olodaterol
and tiotropium [56]. The delivered dose is 2.5 lg
tiotropium (as bromide monohydrate) and
2.5 lg olodaterol (as hydrochloride) per puff.
The device works by forcing a metered dose of
the drug solution through a precisely engi-
neered nozzle, producing two fine jets of liquid
that converge at a preset angle; this generates an
aerosol cloud (the soft mist) [57]. The aerosol
spray exits the Respimat more slowly and for a
longer duration than with the pMDIs, resulting
in a higher fraction of fine particles than most
pMDIs and DPIs. This translates into lower
oropharyngeal deposition and consequently
higher lung drug deposition, higher than with a
pMDI [34, 57]. In clinical trials in patients with
COPD, bronchodilator drugs delivered from
Respimat were equally as effective in bron-
chodilation at half the dose delivered from a
pMDI and 3.6 times more effective than the
Handihaler DPI [57]. Respimat was consis-
tently shown to be well accepted by COPD
patients, largely because of its inhalation and
handling characteristics [57]. As the metered
volume is fixed at 15 lL, Respimat is limited to
drugs with adequate solubility in order to deli-
ver the required dose [25, 56]. Additionally, the
patients need to have good dexterity to twist
and open the cap.
CHARACTERISTICS OF LABA/LAMA
INHALER DEVICES: DRUG
DEPOSITION AND AIRFLOW
RESISTANCE
The most important factors that determine drug
deposition in the airways through inhalation
include device characteristics, type of drug for-
mulation, deagglomeration, particle size, oral
and bronchial deposition, aerosol physical
properties (e.g., aerosol velocity), and patient
characteristics (such as inspiratory flow, disease
state, preparation of the device, coordination of
steps) [20, 21]. These factors ultimately deter-
mine patients’ functional and clinical responses
to the treatment. Key device attributes perti-
nent to inhaler choice and patient adherence
include convenience, ease of use, simple
instructions, minimal potential for errors, air-
flow resistance, efficiency of delivery, and cost
[58]. Consequent to the technological advances
in the design of inhaler devices, the newer
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inhaler devices afford a pulmonary drug depo-
sition fraction of 30–50% of the nominal dose
(Table 2), substantially higher than the 10–15%
with older devices [33].
The turbulent force generated by the patient
is responsible for deaggregation of the powder
into smaller particles and hence for the avail-
able amount of optimum-sized particles for
drug deposition. This energy is the product of
the patient’s inspiratory flow and the device’s
intrinsic resistance [32, 59]. As Table 2 shows,
with the low-resistance Breezhaler a much
higher inspiratory flow is generated while
achieving adequate deposition than that
achieved with a higher intrinsic resistance. In
this context, the intrinsic resistance of a DPI
device refers to the inspiratory flow rate
required to release the correct amount of drug.
Accordingly, within the DPI class, there are high
(required inspiratory flow rate 90 L/min), med-
ium (60–90 L/min), and low (\50 L/min)
intrinsic resistance devices [30, 36]. The lower
the device’s intrinsic resistance, the smaller the
effort required from the patient to generate
such airflow, which may be especially
important in patients with severe airflow limi-
tation. However, perturbations in expiratory
airflow are not necessarily predictive of
impaired inspiratory flow rates [60]. Among the
DPIs that deliver LABA/LAMA, Breezhaler has
the lowest airflow resistance, followed by
Ellipta and Genuair [61] (Table 2). Moreover,
a recent study showed that patients with COPD
were able to inhale with the least inspiratory
effort and generate the highest mean PIF via the
Breezhaler inhaler than with the Ellipta and
HandiHaler inhalers, irrespective of patients’
COPD severity, age, or gender [62]. Low resis-
tance characteristics could explain patient-re-
ported ‘‘comfort’’ inhaling through some
devices; the flow rate produced by a standard
pressure drop of 4 kPa was greater using Breez-
haler than other DPI devices in vitro [63]. It is
important to note that for DPIs, the speed of
particles upon ejection from the mouthpiece,
the disaggregation of the drug, the distribution
of drug within the lungs, and the variability of
the effective inhaled dose are optimal only
when the inhalation flow rate and the intrinsic
resistance of the device are balanced [32]. For
Table 2 Device intrinsic airflow resistance influences the inspiratory flow rate that patients can achieve [59] and drug
deposition in lungs with different DPI inhaler devices
Device Measured mean 
airflow resistance*
kPa0.5 L/min
Inspiratory flow 
rate*
(L/min)
Drug deposition in 
lungs# (% of 
nominal dose)
Breezhaler® 0.017 111 43%
Ellipta® 0.027 74 33–49%
Genuair® 0.031 64 32%
Handihaler® 0.058 37 -
Low resistance
High resistance
Moderate resistance
*The pressure drop and corresponding flow rate were measured at a defined pressure point or a constant flow rate (0–100 L/
min) using a test system with a mass flow meter, a differential pressure sensor connected to a sampling tube, a flow control
valve, and vacuum pumps. Inspiratory flow resistance was calculated by linear regression using the method of least-squares
# Combining in vitro mouth–throat deposition measurements, cascade impactor data, and computational fluid dynamics
simulations
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example, a device such as Genuair with low
variability in the aerodynamic characteristics
and medium intrinsic resistance was shown to
combine the positive aspects of achievable flow
rates, consistent and efficient fine particle gen-
eration, and reduced impaction losses in the
upper airways [59]. An in vitro comparison of
four LABA/LAMA inhaler devices through
modeling of the lung deposition showed that
the Respimat, an SMI device, provided the
lowest amount of particles deposited in the
mouth–throat region and the highest amount
reaching all regions of the simulation lung
model, followed by the DPI devices Breezhaler,
Ellipta, and Genuair [63].
Patient demographics and clinical character-
istics may also influence drug delivery; an
assessment of inhalation characteristics showed
that adults with asthma had greater inspiratory
capacity than patients with COPD but children
with asthma had the least capacity [64]. There is
still ambiguity with regards to the effect of
intrinsic resistance on drug deposition. A higher
inspiratory rate with a high intrinsic resistance
device would result in a higher particle deag-
glomeration, but a higher airflow rate would also
lead to increased drug particle velocity, which is
expected to result in higher oropharyngeal drug
deposition. The behavior of the upper airway
may have an impact on drug deposition; in this
regard, studies have assessed how the human
upper airway behaves with different resistances
and geometries of the inhalers and in turn
affects drug deposition [65]. For high-resistance
inhalers, a correlation between maximum
inspiratory pressure (MIP) and change in airway
volume was shown with those exhibiting
expansion in the upper airway having generally
low MIP [66]; a linear relationship was observed
between airway volume changes and maximum
calculated volumetric airflow [66]; evaluation of
the impact of inhalation maneuvers, inhaler
mouthpiece geometries, and a stepped mouth-
piece on the size of the upper airway showed
that enlarged size of the upper airway might
decrease aerosol deposition in the upper airway
and increase lung deposition [67]. Additionally,
a high inspiratory flow rate may be difficult to
attain in children, elderly, and in patients with
severe airflow obstruction in COPD. Lower peak
inspiratory flow rates generated from a DPI,
measured using an In-Check DIAL device, were
observed in patients with COPD or asthma who
were older than 60 years, compared with
younger patients [68]. That said, clinical studies
have shown that most patients were able to use a
high-resistance DPI effectively, even during
exacerbations [55, 60]. Consequently, it has
been suggested that peak inspiratory flow rates
should be measured prior to discharge of
patients admitted for acute COPD exacerbation
and during clinic visits to ensure optimum
device selection and drug delivery of COPD
patients, especially in the elderly, female
patients, and those with short stature [69].
However, we should also consider that achiev-
ing a specific flow rate is also dependent on the
resistance of the device; in this context, high
inspiratory flow rate alone may not be enough
to test the patient’s ability to use a distinct
device. Hence, we suggest that the patient
should be tested on his prescribed device.
Despite the lack of complete understanding of
the relationship between drug deposition and
airflow resistance, DPIs appear to be suitable de-
vices to deliver inhaled medications to patients
with COPD of varying severity. Nevertheless, it
is important to consider that patients with very
severe COPD were not systematically included
in all clinical studies, and as an example patients
who are undergoing acute exacerbations of
COPD, i.e., a hospitalization, are typically not
enrolled in any study, therefore making it diffi-
cult to evaluate the appropriateness of different
types of inhalers.
Ultimately, healthcare professionals and
caregivers should appreciate that on the basis of
the clinical data showing significant efficacy
throughout a wide spectrum of disease severity,
all devices appear to be adequate for use
regardless of their different physical properties.
Thus, it is worthy to consider that clinical out-
comes throughout randomized controlled
studies or in real-life settings may not always be
affected by physical characteristics or theoreti-
cal issues. In other words, one cannot dissociate
the overall clinical efficacy of inhaled medica-
tions for COPD from inhaler specificities and
handling aspects within the context where evi-
dence was generated.
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PREFERENCE FOR LABA/LAMA
INHALER DEVICES
Patients’ and physicians’ preference for a par-
ticular inhaler device influences treatment
adherence in the long-term management of
COPD that in turn affects the treatment
outcomes.
In a large real-word study that assessed
inhaler preference in patients with COPD, the
ease of use, dose delivery recording (delivery
feedback), and dose capacity (single- or multi-
dose) were cited by patients as the most
important device attributes while choosing a
device. Moreover, key factors that patients
considered made the device easier to use were
fewer steps to operate the inhaler, easier coor-
dination of breathing manoeuver, and least
resistance while inhaling [58]. For healthcare
providers, patient satisfaction and ease of use
were considered as the most important attri-
butes when selecting an inhaler device for
patients [58]. Another real-life study assessed
and compared the patients’ preference for
Breezhaler, Genuair, and Respimat in
asthma and COPD outpatients by means of a
device handling questionnaire [70]. In this
study, Genuair and Respimat were the most
liked and were perceived by patients as the
easiest to use. Patients and nurses also perceived
these two devices as the least problematic; it
should be noted that in this study, patients were
not asked to insert the cartridge into the
Respimat device, which remains a vital step
prior to prepare the actuations [70]. Mean
number of attempts required to achieve the first
effective actuation was the highest with the
Breezhaler device, therefore reinforcing the
importance of patient education with a new
device. Respimat proved to be the most pre-
ferred in COPD patients since it was the most
liked and its success rate at first attempt was the
highest. Furthermore, previous experience with
DPIs and/or MDIs did not affect preference for
an individual device in patients with COPD or
asthma [71]. Respimat was preferred over the
pMDI by patients with COPD and other
obstructive lung diseases [71]. In comparative
studies with pMDIs, the patient total
satisfaction score with Respimat was statisti-
cally and clinically significantly higher than
with the comparator pMDI [71]. In a cross-sec-
tional study among patients with COPD in
Spain using the validated Patient Satisfaction
and Preference Questionnaire (PASAPQ),
patients reported satisfaction with both Respi-
mat and Breezhaler devices [72].
Several studies were previously carried out to
compare ease of use and patient satisfaction
with commercially available inhalers. While all
devices tested in a non-interventional setting
were deemed acceptable to patients, statistically
significant differences were nevertheless
observed in the questionnaire ratings from dif-
ferent inhalers [73]. Notably, patients with sev-
ere COPD expressed a higher feeling of
satisfaction with their devices than those with
moderate or mild disease, independent of the
device used; this may have been due to the
longer use, familiarity with the device, and
probably better adherence (because of their
severe symptoms) of patients with severe COPD
[73]. In DPI-naı̈ve patients with COPD, Breez-
haler was preferred over HandiHaler and was
more likely to be used correctly [74]. A real-life
study evaluated inhaler preference and han-
dling errors with the Ellipta and Breezhaler
DPIs in device-naı̈ve Japanese volunteers aged
40 years or older [75]. It was observed that
Ellipta DPI was preferred over Breezhaler on
the basis of its ease-of-use features and was
associated with fewer handling errors [75]. In
contrast, in the ADVANTAGE study, device-
naı̈ve patients with COPD reported greater
preference for the Breezhaler than for the
Ellipta device for confidence of dose delivery
and comfort of the mouthpiece [76]. Such dif-
ferences may be linked to the larger mouthpiece
of the Breezhaler as well as to the ability for
patients to visually confirm if any powder is left
in the capsule after each actuation. These results
were confirmed in the recent Real life Experi-
ence and Accuracy of inhaLer use (REAL) survey
conducted in patients with COPD, which gath-
ered insights into real-life inhaler use by
patients and healthcare providers, device attri-
butes, and training [77]. The majority of
patients using Breezhaler reported either being
very confident or confident of having taken a
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full dose, which was higher than those using
Genuair, Ellipta, and Respimat. However,
this study also identified a low incidence of
patient training and monitoring by healthcare
providers for correct inhaler use [77]. In the
recently reported INHALATOR study, a signifi-
cantly greater proportion of patients expressed
preference for Breezhaler than for Respimat
(57.1% versus 30.1%) [78]. It should be noted
that good clinical practice implies that patients
are educated on how to use a new device upon
first encounter, while the INHALATOR study
design was apparently relying on patients
familiarizing themselves with the new device
via product leaflets; also, the study was meant to
evaluate the correct use and satisfaction rather
than the efficacy between devices [78]. It is
important to note that differences in active
drug in each of the devices evaluated, among
other limitations in the INHALATOR study,
may have influenced the overall results.
It is noteworthy that in the inhaler device
preference studies that were sponsored by the
pharmaceutical companies, the sponsor’s device
seemed favored by the type of questions asked
to participants and typically came out as a pre-
ferred choice in most of the studies. Unsurpris-
ingly, these observations suggest an intent to
highlight differential device specificities.
Patients with unstable disease or who were
unable to use inhalers were usually excluded
and the extent of instruction and coaching
given in the studies was highly variable. Inter-
estingly, some studies sponsored by pharma-
ceutical companies found no significant
differences in terms of patient satisfaction
between different types of devices (including
DPIs and SMI) [58, 70, 79]. On the other hand,
and as discussed in the following section of this
review, studies including CRITIKAL [24] and
INHALER [45] showed different specific errors
associated with different inhaler devices. These
studies, along with a recent systematic review,
demonstrated the impact of critical errors in
handling inhaler devices on health outcomes in
patients with COPD and asthma [80].
There have been no well-designed studies
that attempted to evaluate how differences
among the devices would translate in terms of
relevant patient outcomes. Moreover, patient
preference is as important as clinical evidence
when selecting an appropriate device and ulti-
mately in realizing optimal clinical outcomes;
therefore, improved patient education,
patient–physician interaction, and affordability
along with greater ease of using inhaler devices
would lead to correct inhaler choice.
HANDLING OF INHALER DEVICES
In randomized clinical studies that compare
inhaled treatments in COPD, the correct use of
inhaler devices is an inclusion criterion. How-
ever, in real life, patients continue to make
errors with their usual inhaler device [81],
which may negate the treatment benefits
observed in clinical studies. In this regard, var-
ious studies have assessed inhaler handling in
real life. It has been shown that most inhaler
users not only make errors but also those
patients who did not get proper education on
inhaler technique are more inclined to misuse
their device [82]. A recent Japanese study has
also suggested that patients, regardless of hav-
ing asthma or COPD, require to be instructed at
least three times, i.e., given demonstrations by
trained personnel in order to limit inhaler
handling errors [83]. Notably, while about 65%
of patients made at least one handling error that
could affect the efficacy after an initial guidance
on how to use the Breezhaler, the Ellipta or
Respimat, more than 90% of patients using
any device could successfully learn the correct
use after receiving guidance from pharmacists
three times successively [83]. Whether inhaler
handling errors remain frequent among long-
term inhaler users or are associated with worse
clinical outcomes in COPD is discussed below.
The real-life INHALER study assessed inhaler
device handling in approximately 3000 COPD
patients who were using inhaler devices for at
least 1 month [45]. Physicians assessed patients’
inhaler technique and documented device-de-
pendent (i.e., specific) or device-independent
handling errors. Handling errors were observed
in over 50% of inhalations regardless of the
device used. However, the number of errors
deemed critical (i.e., those which significantly
reduced drug delivery) differed amongst the
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devices. Device-independent errors (e.g., patient
did not exhale fully prior to inhalation) were
equally frequent across all devices. Fewer
patients made critical errors using Breezhaler
versus other devices; Breezhaler also had fewer
device-specific errors. Overall, fewer critical
errors were made with DPIs than with pMDIs or
SMIs. Moreover, the recent INHALATOR study
showed that the rate of correct device use, i.e.,
no critical errors during inhalation technique,
was similar between Breezhaler and Respi-
mat. The evaluation of the patients’ inhalation
technique was based on the investigator’s
observation [78].
An important finding of the aforementioned
INHALER study was that the handling errors
were significantly associated with more fre-
quent COPD exacerbations (Fig. 1) [45].
Use of Genuair was associated with fewer
errors compared with HandiHaler, including
critical errors that may impede the delivery of
sufficient doses or drug deposition to the lungs
[52, 54]. In an assessment of critical inhaler
technique errors with Genuair and Breezhaler
after 2 weeks of daily use, the proportion of
patients making these errors was low with both
Genuair and Breezhaler [84]. When com-
pared with other inhalers, fewer COPD patients
had at least one overall error using the Ellipta
inhaler compared with the Handihaler or
Breezhaler; a larger proportion of patients
rated the Ellipta inhaler very easy or easy to
use compared with the Handihaler or the
Breezhaler [85]. A cross-sectional study exam-
ined specific patient characteristics and device
attributes that are associated with poor han-
dling technique among patients with COPD
who used at least one of the following devices:
MDI, Diskus, and Handihaler [86]. It was
found that poor inhaler technique was common
among individuals with COPD, varied amongst
devices, and was even associated with race and
level of education [86]. A real-life study com-
pared handling of different inhaler devices
(Aerolizer, Autohaler, Diskus, or Tur-
buhaler) in primary care practice in France and
observed differences in device handling in pri-
mary care that were not considered in con-
trolled studies [87]. Although this study did not
compare devices that deliver LABA/LAMA FDCs,
a comparison of findings from this study and
those from the INHALER study [45] indicates
that device handling has not improved signifi-
cantly over the several decades that handling
studies have been performed.
#exacerbation with antibiotic therapy, corticosteroid therapy, emergency room visit or hospitalization.
*exacerbation with emergency room visits or hospitalization.
†restricted to patients treated for at least 3 months with the device.
Fig. 1 Association of critical device handling errors with COPD exacerbations
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EFFECTIVE TREATMENT THROUGH
APPROPRIATE APPLICATION
OF INHALER DEVICES
The inhaled route of administration is consid-
ered as the best way to deliver medications to
patients with COPD. The availability of an array
of medication classes and associated inhaler
devices with different degrees of efficacy has
actually made the selection of optimal inhaled
treatment complicated.
Ideally, inhalers should be easy to use and
should have multiple feedback and control
mechanisms that would reduce physician over-
estimation and ignorance of correct inhalation,
allow compliance to be monitored, facilitate
patient self-education, and give reassurance to
patients in routine care. Treatment compliance
in long-term disease management may be
improved by educating patients and physicians
on the correct use of inhaler devices. In this
regard, studies such as the REAL survey have
attempted to assess the effectiveness of patient/
healthcare provider training on correct inhaler
use [77]. Poor inhalation technique, number of
inhalation steps, clinical setting, and time
elapsed since training were shown to have an
impact on the effectiveness of the educa-
tional/training intervention [77]. Educational
interventions to improve inhaler technique in
patients were found to be effective in the short
term [77]. To improve application of inhaler
devices in real life, the German Airway League
developed a checklist for inhaler devices to
check for inhaler errors. Moreover, they pre-
pared free internet-based short videos for all
available inhaler devices. It was shown that a
single session of patient information through a
short video sequence improved device use, and
the effect lasted for 4–8 weeks [88–90]. Video
information seemed to be very important in
improving inhalation technique, since health-
care personnel in primary care and hospitals are
often not qualified for use of different inhaler
devices [91, 92].
A number of factors influence treatment
outcomes with inhalation therapy (Fig. 2). In
particular, characteristics of the drug and of the
delivery device, patient’s ability to use a device
properly, education/training, and patient’s per-
sonal preference should be considered in order
to maximize treatment outcome through
inhalation therapy [6, 93]. However, one should
interpret device preference studies cautiously as
Fig. 2 Factors influencing treatment outcomes from inhaler devices
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they often focus on handling-related preferences
and are frequently conducted with patients
using placebo devices, therefore discarding some
important aspects of inhaled medications. These
include the patient’s ability to self-monitor
adequate use of the device and uptake inhaled
medication, as well as the clinical benefits of the
inhaled therapy as perceived by the patients
[94]. These factors have the potential to support
patients’ adherence and satisfaction and deserve
physicians’ consideration. Highlighting the
association of inhaler device application with
clinical outcomes, Molimard et al. showed for
the first time that, despite limitations of their
study (e.g., short follow-up period), inhaler
misuse may be linked to increased rates of severe
exacerbations in COPD patients [45].
As inhaled medications are essentially ‘‘inte-
grated’’ with their respective devices, the chal-
lenge in ensuring the best possible application of
inhaled treatment is in identifying whether the
empirical clinical efficacy of the delivered mole-
cules or the differential inhaler use (more/less
clinical errors, or variable patient behaviors
using different devices) determines the observed
treatment efficacy. Even a randomized head-to-
head comparison of different LABA/LAMA FDCs
would be limited as the comparison is often
made between different medications (even
though of the same class) in different devices. A
possible solution could be more head-to-head
studies of different inhalers (e.g., administering
placebo to remove medication bias or using a
double-dummy design wherein all patients use
all inhalers, but some will be placebo).
CONCLUSIONS
Inhaler devices that offer consistent and effi-
cient dosing, ease of use, and patient preference
lead to enhanced patient adherence and there-
fore better treatment efficacy. Nonetheless,
handling errors are common and numerous
patient factors still limit the use of contempo-
rary devices. Such suboptimal inhaler use has an
adverse effect on clinical outcomes. The GOLD
2019 strategy has re-emphasized consideration
of inhaler device attributes and handling while
prescribing treatment to COPD patients. In this
context, GOLD has explicitly stated that the
importance of education and training in inhaler
device technique cannot be overemphasized.
It is important that a patient’s ability to use
an inhaler device is checked by the healthcare
provider at the first visit and monitored at each
subsequent visit, ideally every 3 months for a
minimum of 1 year. Assessment of inhaler
technique and adherence has been recognized
by GOLD as an essential component of the
management of stable COPD. Therefore, patient
education and patient–healthcare provider
interactions are key to ensuring the correct use
of inhaler devices. Technologic advances may
soon offer assistance. New electronic and
internet-connected inhaler devices, also called
smart inhalers, e.g., eBreezhaler, are in late-
phase development to help with real-time
monitoring of treatment adherence and appro-
priate device use, and even to train patients.
The widespread adoption of smart inhalers
might be limited by concerns over cost-effec-
tiveness, lack of evidence that they improve
quality of life, and increased burden on
healthcare providers to monitor the data [95].
Finally, in view of the gap that still remains
in the selection and application of appropriate
inhaler devices for delivery of optimal COPD
treatment, this review indicates that both the
efficacy of the drug and appropriate application
of inhaler devices cannot be dissociated in the
context of evolving COPD management that
has placed an increasing emphasis on the use of
LABA/LAMA fixed-dose bronchodilator combi-
nations. Although influenced by physician and
patient preferences, the choice of an appropri-
ate inhaler and continuous educational efforts
to reinforce appropriate device handling are of
equal importance to ensure therapies optimally
contribute to the management of COPD.
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inhalation technique using web-based videos in
obstructive lung diseases. Respir Med.
2017;129:140–4.
90. Klijn SL, Hiligsmann M, Evers SMAA, et al. Effec-
tiveness and success factors of educational inhaler
technique interventions in asthma and COPD
patients: a systematic review. NPJ Prim Care Respir
Med. 2017;27(1):24.
91. Hanania NA, Wittman R, Kesten S, et al. Medical
personnel’s knowledge of and ability to use inhal-
ing devices. Metered-dose inhalers, spacing cham-
bers, and breath-actuated dry powder inhalers.
Chest. 1994;105(1):111–6.
92. Lavorini F, Levy ML, Dekhuijzen PN. Inhaler choice
and inhalation technique: key factors for asthma
control. Prim Care Respir J. 2009;18(4):241–2.
93. Mahler DA, Ward J, Fierro-Carrion G, et al. Devel-
opment of self-administered versions of modified
40 Pulm Ther (2019) 5:23–41
baseline and transition dyspnea indexes in COPD.
COPD. 2004;1(2):165–72.
94. Dixon LC, Ward DJ, Smith J, et al. New and
emerging technologies for the diagnosis and mon-
itoring of chronic obstructive pulmonary disease: a
horizon scanning review. Chronic Respir Dis.
2016;13(4):321–36.
95. Wieshammer S, Dreyhaupt J. Dry powder inhalers:
which factors determine the frequency of handling
errors? Respiration. 2008;75(1):18–25.
Pulm Ther (2019) 5:23–41 41
